The last several years have seen an abundance of studies of genetic risk factors for
vascular disease, and platelet glycoprotein (GP) polymorphisms have been a primary
focus of this area of research. This article reviews GP receptor polymorphisms, particularly
those on GPIa-IIa (integrin α2β1), GPIb-IX-V, GPIIb-IIIa (integrin αIIbβ3), and GPVI, and summarizes clinical and functional studies that have attempted to
clarify their roles in human disease. Our focus is on recent work relevant to thrombotic
and hemostatic processes and advances in pharmacogenetics. We consider issues affecting
our ability to derive firm conclusions from these studies, and discuss future directions
in this rapidly evolving area.
KEYWORDS
Glycoprotein polymorphisms - platelet reactivity - thrombosis - pharmacogenetics
REFERENCES
- 1 Afshar-Kharghan V, Bray P F. Platelet polymorphisms. In: Michelson AD Platelets
Academic Press 2002: 157-169
- 2
Bray P F.
Platelet glycoprotein polymorphisms as risk factors for thrombosis.
Curr Opin Hematol.
2000;
7
284-289
- 3 Bussel J B, Kunicki T J, Michelson A D. Platelets: New Understanding of Platelet
Glycoproteins and Their Role in Disease. Hematology Washington, DC; American Society
of Hematology 2000: 222-240
- 4
Reiner A P, Siscovick D S, Rosendaal F R.
Platelet glycoprotein gene polymorphisms and risk of thrombosis: facts and fancies.
Rev Clin Exp Hematol.
2001;
5
262-287
- 5
Furman M I, Benoit S E, Barnard M R et al..
Increased platelet reactivity and circulating monocyte-platelet aggregates in patients
with stable coronary artery disease.
J Am Coll Cardiol.
1998;
31
352-358
- 6
Kabbani S S, Watkins M W, Ashikaga T et al..
Platelet reactivity characterized prospectively: a determinant of outcome 90 days
after percutaneous coronary intervention.
Circulation.
2001;
104
181-186
- 7
Trip M D, Cats V M, van Capelle F J, Vreeken J.
Platelet hyperreactivity and prognosis in survivors of myocardial infarction.
N Engl J Med.
1990;
322
1549-1554
- 8
Wood J, Dong J F, Yee D L et al..
Evaluating platelet hyperreactivity for arterial thrombosis risk.
Blood.
2003;
102
93A
- 9
Weiss E J, Bray P F, Tayback M et al..
A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for
coronary thrombosis.
N Engl J Med.
1996;
334
1090-1094
- 10
Clemetson K J, Clemetson J M.
Platelet collagen receptors.
Thromb Haemost.
2001;
86
189-197
- 11
Moshfegh K, Wuillemin W A, Redondo M et al..
Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with
risk of myocardial infarction: a case-control study.
Lancet.
1999;
353
351-354
- 12
Casorelli I, De Stefano V, Leone A M et al..
The C807T/G873A polymorphism in the platelet glycoprotein Ia gene and the risk of
acute coronary syndrome in the Italian population.
Br J Haematol.
2001;
114
150-154
- 13
Roest M, Banga J D, Grobbee D E et al..
Homozygosity for 807 T polymorphism in {alpha}2 subunit of platelet {alpha}2{beta}1
is associated with increased risk of cardiovascular mortality in high-risk women.
Circulation.
2000;
102
1645-1650
- 14
Santoso S, Kunicki T J, Kroll H, Haberbosch W, Gardemann A.
Association of the platelet glycoprotein Ia C807T gene polymorphism with nonfatal
myocardial infarction in younger patients.
Blood.
1999;
93
2449-2453
- 15
Meisel C, Cascorbi I, Herrmann A et al..
The platelet glycoprotein Ia C807T polymorphism as risk factor for coronary catheter
interventions.
Blood.
2000;
96
2002-2003
- 16
von Beckerath N, Koch W, Mehilli J et al..
Glycoprotein Ia gene C807T polymorphism and risk for major adverse cardiac events
within the first 30 days after coronary artery stenting.
Blood.
2000;
95
3297-3301
- 17
Carlsson L E, Santoso S, Spitzer C, Kessler C, Greinacher A.
The alpha 2 gene coding sequence T807/A873 of the platelet collagen receptor integrin
alpha 2beta 1 might be a genetic risk factor for the development of stroke in younger
patients.
Blood.
1999;
93
3583-3586
- 18
Reiner A P, Kumar P N, Schwartz S M et al..
Genetic variants of platelet glycoprotein receptors and risk of stroke in young women.
Stroke.
2000;
31
1628-1633
- 19
Kunicki T J, Kritzik M, Annis D S, Nugent D J.
Hereditary variation in platelet integrin alpha 2 beta 1 density is associated with
two silent polymorphisms in the alpha 2 gene coding sequence.
Blood.
1997;
89
1939-1943
- 20
Kritzik M, Savage B, Nugent D J et al..
Nucleotide polymorphisms in the alpha2 gene define multiple alleles that are associated
with differences in platelet alpha2 beta1 density.
Blood.
1998;
92
2382-2388
- 21
Corral J, Gonzalez-Conejero R, Rivera J et al..
Role of the 807 C/T polymorphism of the alpha2 gene in platelet GP Ia collagen receptor
expression and function-effect in thromboembolic diseases.
Thromb Haemost.
1999;
81
951-956
- 22
Jacquelin B, Rozenshteyn D, Kanaji S et al..
Characterization of inherited differences in transcription of the human integrin alpha
2 gene.
J Biol Chem.
2001;
276
23518-23524
- 23
Lopez J A, Dong J F.
Structure and function of the glycoprotein Ib-IX-V complex.
Curr Opin Hematol.
1997;
4
323-329
- 24
Coller B S, Peerschke E I, Scudder L E, Sullivan C A.
Studies with a murine monoclonal antibody that abolishes ristocetin-induced binding
of von Willebrand factor to platelets: additional evidence in support of GPIb as a
platelet receptor for von Willebrand factor.
Blood.
1983;
61
99-110
- 25
Yamamoto N, Kitagawa H, Tanoue K, Yamazaki H.
Monoclonal antibody to glycoprotein Ib inhibits both thrombin- and ristocetin-induced
platelet aggregations.
Thromb Res.
1985;
39
751-759
- 26
Dormann D, Clemetson K J, Kehrel B E.
The GPIb thrombin-binding site is essential for thrombin-induced platelet procoagulant
activity.
Blood.
2000;
96
2469-2478
- 27
Afshar-Kharghan V, Matijevic-Aleksic N, Ahn C et al..
The variable number of tandem repeat polymorphism of platelet glycoprotein Ib{alpha}
and risk of coronary heart disease.
Blood.
2004;
103
963-965
- 28
Baker R I, Eikelboom J, Lofthouse E et al..
Platelet glycoprotein Ib{alpha} Kozak polymorphism is associated with an increased
risk of ischemic stroke.
Blood.
2001;
98
36-40
- 29
Gonzalez-Conejero R, Lozano M L, Rivera J et al..
Polymorphisms of platelet membrane glycoprotein Ibalpha associated with arterial thrombotic
disease.
Blood.
1998;
92
2771-2776
- 30
Kenny D, Muckian C, Fitzgerald D J, Cannon C P, Shields D C.
Platelet glycoprotein Ib alpha receptor polymorphisms and recurrent ischaemic events
in acute coronary syndrome patients.
J Thromb Thrombolysis.
2002;
13
13-19
- 31
Mikkelsson J, Perola M, Penttila A, Karhunen P J.
Platelet glycoprotein Ib{alpha} HPA-2 Met/VNTR B haplotype as a genetic predictor
of myocardial infarction and sudden cardiac death.
Circulation.
2001;
104
876-880
- 32
Murata M, Matsubara Y, Kawano K et al..
Coronary artery disease and polymorphisms in a receptor mediating shear stress-dependent
platelet activation.
Circulation.
1997;
96
3281-3286
- 33
Sonoda A, Murata M, Ikeda Y, Fukuuchi Y, Watanabe K.
Stroke and platelet glycoprotein Ibalpha polymorphisms.
Thromb Haemost.
2001;
85
573-574
- 34
Sonoda A, Murata M, Ito D et al..
Association between platelet glycoprotein Ib{alpha} genotype and ischemic cerebrovascular
disease.
Stroke.
2000;
31
493-497
- 35
Ulrichts H, Vanhoorelbeke K, Cauwenberghs S et al..
Von Willebrand factor but not {alpha}-thrombin binding to platelet glycoprotein ib{alpha}
is influenced by the HPA-2 polymorphism.
Arterioscler Thromb Vasc Biol.
2003;
23
1302-1307
- 36
Yee D L, Wood J, Bergeron A et al..
Thr-145 and VNTR C/D polymorphisms on glycoprotein Iba demonstrate increased platelet
reactivity to shear stress and ristocetin.
Blood.
2003;
102
783A
- 37
Corral J, Lozano M L, Gonzalez-Conejero R et al..
A common polymorphism flanking the ATG initiator codon of GPIb alpha does not affect
expression and is not a major risk factor for arterial thrombosis.
Thromb Haemost.
2000;
83
23-28
- 38
Afshar-Kharghan V, Li C Q, Khoshnevis-Asl M, Lopez J A.
Kozak sequence polymorphism of the glycoprotein (GP) Ibalpha gene is a major determinant
of the plasma membrane levels of the platelet GP Ib-IX-V complex.
Blood.
1999;
94
186-191
- 39
Newman P J, Derbes R S, Aster R H.
The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33
amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by
DNA typing.
J Clin Invest.
1989;
83
1778-1781
- 40
Marian A J, Brugada R, Kleiman N S.
Platelet glycoprotein IIIa PlA polymorphism and myocardial infarction.
N Engl J Med.
1996;
335
1071-1072
- 41
Bray P F, Weiss E J, Tayback M, Goldschmidt-Clermont P J.
PlA1/A2 polymorphism of platelet glycoprotein IIIa and risk of cardiovascular disease.
Lancet.
1997;
349
1100-1101
- 42
Ridker P M, Stampfer M J.
Assessment of genetic markers for coronary thrombosis: promise and precaution.
Lancet.
1999;
353
687-688
- 43
Mikkelsson J, Perola M, Laippala P et al..
Glycoprotein IIIa PlA polymorphism associates with progression of coronary artery
disease and with myocardial infarction in an autopsy series of middle-aged men who
died suddenly.
Arterioscler Thromb Vasc Biol.
1999;
19
2573-2578
- 44
Mikkelsson J, Perola M, Laippala P, Penttila A, Karhunen P J.
Glycoprotein IIIa Pl(A1/A2) polymorphism and sudden cardiac death.
J Am Coll Cardiol.
2000;
36
1317-1323
- 45
Walter D H, Schachinger V, Elsner M, Dimmeler S, Zeiher A M.
Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis.
Lancet.
1997;
350
1217-1219
- 46
Kastrati A, Schomig A, Seyfarth M et al..
PlA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary
stent placement.
Circulation.
1999;
99
1005-1010
- 47
Zotz R B, Klein M, Dauben H P et al..
Prospective analysis after coronary-artery bypass grafting: platelet GP IIIa polymorphism
(HPA-1b/PIA2) is a risk factor for bypass occlusion, myocardial infarction, and death.
Thromb Haemost.
2000;
83
404-407
- 48
Di Castelnuovo A, de Gaetano G, Donati M B, Iacoviello L.
Platelet glycoprotein receptor IIIa polymorphism PLA1/PLA2 and coronary risk: a meta-analysis.
Thromb Haemost.
2001;
85
626-633
- 49
Wu A H, Tsongalis G J.
Correlation of polymorphisms to coagulation and biochemical risk factors for cardiovascular
diseases.
Am J Cardiol.
2001;
87
1361-1366
- 50
Boekholdt S M, Peters R J, de Maat M P et al..
Interaction between a genetic variant of the platelet fibrinogen receptor and fibrinogen
levels in determining the risk of cardiovascular events.
Am Heart J.
2004;
147
181-186
- 51
Bojesen S E, Tybjaerg-Hansen A, Nordestgaard B G.
Integrin {beta}3 Leu33Pro homozygosity and risk of cancer.
J Natl Cancer Inst.
2003;
95
1150-1157
- 52
Tschoepe D, Menart B, Ferber P et al..
Genetic variation of the platelet- surface integrin GPIIb-IIIa (PIA1/A2-SNP) shows
a high association with Type 2 diabetes mellitus.
Diabetologia.
2003;
46
984-989
- 53
Michelson A D, Furman M I, Goldschmidt-Clermont P et al..
Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists.
Circulation.
2000;
101
1013-1018
- 54
Lasne D, Krenn M, Pingault V et al..
Interdonor variability of platelet response to thrombin receptor activation: influence
of PlA2 polymorphism.
Br J Haematol.
1997;
99
801-807
- 55
Bennett J S, Catella-Lawson F, Rut A R et al..
Effect of the PlA2 alloantigen on the function of {beta}3-integrins in platelets.
Blood.
2001;
97
3093-3099
- 56
Vijayan K V, Goldschmidt-Clermont P J, Roos C, Bray P F.
The PlA2 polymorphism of integrin {beta}3 enhances outside-in signaling and adhesive
functions.
J Clin Invest.
2000;
105
793-802
- 57
Vijayan K V, Liu Y, Sun C, Bray P F.
The Pro33 isoform of integrin beta3 enhances outside-in signaling by regulating the
activation of serine/threonine phosphatases.
Blood.
2003;
102
161A
- 58
Vijayan K V, Huang T C, Liu Y et al..
Shear stress augments the enhanced adhesive phenotype of cells expressing the Pro33
isoform of integrin beta3.
FEBS Lett.
2003;
540
41-46
- 59
Croft S A, Samani N J, Teare M D et al..
Novel platelet membrane glycoprotein VI dimorphism is a risk factor for myocardial
infarction.
Circulation.
2001;
104
1459-1463
- 60
Takagi S, Iwai N, Baba S et al..
A GPVI polymorphism is a risk factor for myocardial infarction in Japanese.
Atherosclerosis.
2002;
165
397-398
- 61
Cole V J, Staton J M, Eikelboom J W et al..
Collagen platelet receptor polymorphisms integrin alpha2beta1 C807T and GPVI Q317L
and risk of ischemic stroke.
J Thromb Haemost.
2003;
1
963-970
- 62
Furihata K, Clemetson K J, Deguchi H, Kunicki T J.
Variation in human platelet glycoprotein VI content modulates glycoprotein VI-specific
prothrombinase activity.
Arterioscler Thromb Vasc Biol.
2001;
21
1857-1863
- 63
Chen H, Locke D, Liu Y, Liu C, Kahn M L.
The platelet receptor GPVI mediates both adhesion and signaling responses to collagen
in a receptor density-dependent fashion.
J Biol Chem.
2002;
277
3011-3019
- 64
Best D, Senis Y A, Jarvis G E et al..
GPVI levels in platelets: relationship to platelet function at high shear.
Blood.
2003;
102
2811-2818
- 65
Joutsi-Korhonen L, Smethurst P A, Rankin A et al..
The low-frequency allele of the platelet collagen signaling receptor glycoprotein
VI is associated with reduced functional responses and expression.
Blood.
2003;
101
4372-4379
- 66
Ridker P M, Hennekens C H, Schmitz C, Stampfer M J, Lindpaintner K.
PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction,
stroke, and venous thrombosis.
Lancet.
1997;
349
385-388
- 67
Di Paola J, Federici A B, Mannucci P M et al..
Low platelet alpha 2beta 1 levels in type I von Willebrand disease correlate with
impaired platelet function in a high shear stress system.
Blood.
1999;
93
3578-3582
- 68
Ghosh K, Kulkarni B, Nair S, Shetty S, Mohanty D.
Human platelet alloantigen polymorphism in Glanzmann’s thrombasthenia and its impact
on the severity of the disease.
Br J Haematol.
2002;
119
348-353
- 69
Pereira J, Quiroga T, Pereira M E et al..
Platelet membrane glycoprotein polymorphisms do not influence the clinical expressivity
of von Willebrand disease type 1.
Thromb Haemost.
2003;
90
1135-1140
- 70
Gum P A, Kottke-Marchant K, Poggio E D et al..
Profile and prevalence of aspirin resistance in patients with cardiovascular disease.
Am J Cardiol.
2001;
88
230-235
- 71
Buchanan M R, Brister S J.
Individual variation in the effects of ASA on platelet function: implications for
the use of ASA clinically.
Can J Cardiol.
1995;
11
221-227
- 72
Steinhubl S R, Varanasi J S, Goldberg L, Varinasi J S.
Determination of the natural history of aspirin resistance among stable patients with
cardiovascular disease.
J Am Coll Cardiol.
2003;
42
1336-1337
- 73
Andrioli G, Minuz P, Solero P et al..
Defective platelet response to arachidonic acid and thromboxane A(2) in subjects with
Pl(A2) polymorphism of beta(3) subunit (glycoprotein IIIa).
Br J Haematol.
2000;
110
911-918
- 74
Undas A, Brummel K, Musial J, Mann K G, Szczeklik A.
Pl(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation
and impaired antithrombotic action of aspirin at the site of microvascular injury.
Circulation.
2001;
104
2666-2672
- 75
Bihour C, Durrieu-Jais C, Macchi L et al..
Expression of markers of platelet activation and the interpatient variation in response
to abciximab.
Arterioscler Thromb Vasc Biol.
1999;
19
212-219
- 76
Holmes M B, Sobel B E, Schneider D J.
Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide
in blood from healthy subjects.
Am J Cardiol.
1999;
84
203-207
- 77
Rozalski M, Watala C.
Antagonists of platelet fibrinogen receptor are less effective in carriers of Pl(A2)
polymorphism of beta(3) integrin.
Eur J Pharmacol.
2002;
454
1-8
- 78
Wheeler G L, Braden G A, Bray P F et al..
Reduced inhibition by abciximab in platelets with the PlA2 polymorphism.
Am Heart J.
2002;
143
76-82
- 79
Weber A A, Jacobs C, Meila D et al..
No evidence for an influence of the human platelet antigen-1 polymorphism on the antiplatelet
effects of glycoprotein IIb/IIIa inhibitors.
Pharmacogenetics.
2002;
12
581-583
- 80
O'Connor F F, Shields D C, Fitzgerald A et al..
Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses
to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes.
Blood.
2001;
98
3256-3260
- 81
Walter D H, Schachinger V, Elsner M et al..
Statin therapy is associated with reduced restenosis rates after coronary stent implantation
in carriers of the Pl(A2)allele of the platelet glycoprotein IIIa gene.
Eur Heart J.
2001;
22
587-595
- 82
Bray P F, Cannon C P, Goldschmidt-Clermont P et al..
The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms
and the risk of recurrent events after acute myocardial infarction.
Am J Cardiol.
2001;
88
347-352
- 83
Borecki I B, Suarez B K.
Linkage and association: basic concepts.
Adv Genet.
2001;
42
45-66
- 84
Kruglyak L.
Prospects for whole-genome linkage disequilibrium mapping of common disease genes.
Nat Genet.
1999;
22
139-144
- 85
Huttley G A, Smith M W, Carrington M, O'Brien S J.
A scan for linkage disequilibrium across the human genome.
Genetics.
1999;
152
1711-1722
- 86
Stephens J C, Schneider J A, Tanguay D A et al..
Haplotype variation and linkage disequilibrium in 313 human genes.
Science.
2001;
293
489-493
Paul F BrayM.D.
Department of Medicine, Thrombosis Research Section, Baylor College of Medicine
BCM 286, N 1319, Houston, TX 77030
Email: pbray@bcm.tmc.edu